DERMATA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3397 USD | -3.33% |
|
+27.47% | -44.31% |
| Mar. 21 | Dermata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Jan. 05 | Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected | MT |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 2.34M |
|---|---|---|---|---|---|
| Net income 2024 * | -12M | Net income 2025 * | -14M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-0.25
x | P/E ratio 2025 * |
-0.53
x | Employees | 8 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.15% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -3.33% | ||
| 1 week | +27.47% | ||
| Current month | -17.31% | ||
| 1 month | -18.18% | ||
| 3 months | -18.85% | ||
| 6 months | -46.92% | ||
| Current year | -44.31% |
1 week
0.26
0.36
1 month
0.230.44
Current year
0.230.89
1 year
0.233.68
3 years
0.23111.20
5 years
0.23111.20
10 years
0.23111.20
| Managers | Title | Age | Since |
|---|---|---|---|
Gerry Proehl
CEO | Chief Executive Officer | 65 | 14-12-07 |
David Hale
FOU | Founder | 75 | 14-12-07 |
Kyri van Hoose
DFI | Director of Finance/CFO | - | 21-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Hale
FOU | Founder | 75 | 14-12-07 |
Gerry Proehl
CEO | Chief Executive Officer | 65 | 14-12-07 |
Wendell Wierenga
BRD | Director/Board Member | 76 | 16-09-19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 0.3397 | -3.33% | 19 498 |
| 24-04-22 | 0.3514 | +9.44% | 37,777 |
| 24-04-19 | 0.3211 | -5.06% | 28,521 |
| 24-04-18 | 0.3382 | +14.68% | 277,490 |
| 24-04-17 | 0.2949 | +10.66% | 130,213 |
Delayed Quote Nasdaq, April 23, 2024 at 03:57 pm EDT
More quotes
Dermata Therapeutics, Inc. is a late-stage medical dermatology company. The Company is focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, both incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its lead product candidate, DMT310, is intended to utilize its Spongilla technology for once weekly treatment of a variety of skin diseases, with its initial focus being the treatment of acne vulgaris, which has a United States market size of approximately 50 million patients. Its second product candidate utilizing its Spongilla technology is DMT410, its combination treatment. DMT410 is intended to consist of one treatment of its proprietary sponge powder followed by one topical application of botulinum toxin for delivery into the dermis.
Calendar
2024-05-07
- Annual General Meeting
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.3514
USD
Average target price
1.5
USD
Spread / Average Target
+326.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -44.31% | 2.34M | |
| -0.49% | 103B | |
| +3.31% | 96.73B | |
| +1.66% | 21.31B | |
| -16.16% | 21.21B | |
| -6.82% | 18.79B | |
| -41.41% | 16.37B | |
| -22.87% | 13.68B | |
| +6.32% | 13.44B | |
| +21.46% | 10.98B |
- Stock Market
- Equities
- DRMA Stock
